[Infographics] TRIDENT-1 High ORR, long DoR with repotrectinib in TKI-naïve and -pretreated ROS1+ NSCLC, including Asian patients

29 Oct 2025
[Infographics] TRIDENT-1 High ORR, long DoR with repotrectinib in TKI-naïve and -pretreated ROS1+ NSCLC, including Asian pati

The phase I/II TRIDENT-1 trial demonstrates high ORR and durable activity of repotrectinib, a next-generation TKI, in TKI-naïve and -pretreated ROS1+ or NTRK1–3+ locally advanced or metastatic NSCLC, including patients from Asia.


For academic reference only by medical and healthcare professionals.

Resources

[Infographics] TRIDENT-1: High ORR, long DoR with repotrectinib in TKI-naïve and -pretreated ROS1+ NSCLC, including Asian pat

[Infographics] TRIDENT-1: High ORR, long DoR with repotrectinib in TKI-naïve and -pretreated ROS1+ NSCLC, including Asian patients

[Infographics] TRIDENT-1: High ORR, long DoR with repotrectinib in TKI-naïve and -pretreated ROS1+ NSCLC, including Asian pat

[Infographics] TRIDENT-1: High ORR, long DoR with repotrectinib in TKI-naïve and -pretreated ROS1+ NSCLC, including Asian patients